Toxicological and pharmacokinetic effects following coadministration of brequinar sodium and cyclosporine to Sprague-Dawley rats.
Barnes
T B
TB
Safety Assessment and Drug Metabolism and Pharmacokinetic Section, Du Pont Merck Pharmaceutical Company, Newark, Delaware 19714.
Campbell
P
P
Zajac
I
I
Gayda
D
D
D000284:Administration, Oral; D000818:Animals; D001713:Biphenyl Compounds / Q000493:pharmacokinetics* / Q000633:toxicity*; D016572:Cyclosporine / Q000493:pharmacokinetics* / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D005260:Female; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000633:toxicity*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D011798:Quinaldines
D001713:Biphenyl Compounds; D016572:Cyclosporine; D007166:Immunosuppressive Agents; C046943:brequinar; D011798:Quinaldines